Fusafungine: Difference between revisions
Dietervdwes (talk | contribs) m corrected terminology |
Dietervdwes (talk | contribs) m corrected link |
||
| Line 43: | Line 43: | ||
'''Fusafungine''' ([[International Nonproprietary Name|INN]]), also known as '''fusafungin''', is an active agent used in [[antibiotic]]s for treatment of [[nasal infection|nasal]] and [[throat infection]]. It also possesses [[anti-inflammatory]] properties. Fusafungine is a mixture of [[enniatin]] [[depsipeptide|cyclohexadepsipeptides]] made up of alternating <small>D</small>-α-hydroxyvaleric acid and <small>L</small>-''N''-methylamino acid residues,<ref>{{cite journal | journal = [[Biochemical Pharmacology]] | volume =50 |issue=12 22 |year=1995 |pages= 2105–2107 | title=Alkali cation transport through liposomes by the antimicrobial fusafungine and its constitutive enniatins | author = Daniel Levy, Aline Bluzat, Michel Seigneuret and Jean-Louis Rigaud| doi = 10.1016/0006-2952(95)02045-4 | pmid=8849339}}</ref> produced by the [[Ascomycota|ascomycete]] ''[[Fusarium lateritium]]'', and marketed by [[Servier]] under the trade names '''Locabiotal''', '''Bioparox''', and '''Locabiosol'''. |
'''Fusafungine''' ([[International Nonproprietary Name|INN]]), also known as '''fusafungin''', is an active agent used in [[antibiotic]]s for treatment of [[nasal infection|nasal]] and [[throat infection]]. It also possesses [[anti-inflammatory]] properties. Fusafungine is a mixture of [[enniatin]] [[depsipeptide|cyclohexadepsipeptides]] made up of alternating <small>D</small>-α-hydroxyvaleric acid and <small>L</small>-''N''-methylamino acid residues,<ref>{{cite journal | journal = [[Biochemical Pharmacology]] | volume =50 |issue=12 22 |year=1995 |pages= 2105–2107 | title=Alkali cation transport through liposomes by the antimicrobial fusafungine and its constitutive enniatins | author = Daniel Levy, Aline Bluzat, Michel Seigneuret and Jean-Louis Rigaud| doi = 10.1016/0006-2952(95)02045-4 | pmid=8849339}}</ref> produced by the [[Ascomycota|ascomycete]] ''[[Fusarium lateritium]]'', and marketed by [[Servier]] under the trade names '''Locabiotal''', '''Bioparox''', and '''Locabiosol'''. |
||
According to a pooled analysis study done in the UK for the efficacy of fusafungine in [[rhinopharingitis]], it was found that the proportion of patients who showed an improvement in symptoms from Day 0 to Day 4 of infection was 61.5% with fusafungine vs. 46.8% when compared to a placebo. <ref>http://www.ncbi.nlm.nih.gov/pubmed/15626253</ref> |
According to a pooled analysis study done in the UK for the efficacy of fusafungine in [[Rhinopharyngitis|rhinopharingitis]], it was found that the proportion of patients who showed an improvement in symptoms from Day 0 to Day 4 of infection was 61.5% with fusafungine vs. 46.8% when compared to a placebo. <ref>http://www.ncbi.nlm.nih.gov/pubmed/15626253</ref> |
||
==References== |
==References== |
||
{{reflist}} |
{{reflist}} |
||
Revision as of 15:48, 28 July 2013
| Clinical data | |
|---|---|
| Other names | Fusafungin |
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.014.306 |
| Chemical and physical data | |
| Formula | C29H51N2O8 |
| Molar mass | 555.72 g/mol[1] g·mol−1 |
| (verify) | |
Fusafungine (INN), also known as fusafungin, is an active agent used in antibiotics for treatment of nasal and throat infection. It also possesses anti-inflammatory properties. Fusafungine is a mixture of enniatin cyclohexadepsipeptides made up of alternating D-α-hydroxyvaleric acid and L-N-methylamino acid residues,[2] produced by the ascomycete Fusarium lateritium, and marketed by Servier under the trade names Locabiotal, Bioparox, and Locabiosol.
According to a pooled analysis study done in the UK for the efficacy of fusafungine in rhinopharingitis, it was found that the proportion of patients who showed an improvement in symptoms from Day 0 to Day 4 of infection was 61.5% with fusafungine vs. 46.8% when compared to a placebo. [3]
References
- ^ Fusafungine at MeSH
- ^ Daniel Levy, Aline Bluzat, Michel Seigneuret and Jean-Louis Rigaud (1995). "Alkali cation transport through liposomes by the antimicrobial fusafungine and its constitutive enniatins". Biochemical Pharmacology. 50 (12 22): 2105–2107. doi:10.1016/0006-2952(95)02045-4. PMID 8849339.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ http://www.ncbi.nlm.nih.gov/pubmed/15626253
 | This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
 | This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |